A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Key Points: Carfilzomib 56 mg/m2 provided a high overall response rate with a remarkable duration of response in patients with R/RMM. Nonhematologic grade 3/4 AEs likely related to carfilzomib treatment included hypertension and heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“This study used a Simon optimal 2-stage design.(22) The treatment was considered of interest if the ORR was 30% or more and of no interest if 10% or less.”
MethodA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“This strategy was based on the preclinical findings that suggested synergy between carfilzomib and dexamethasone(2) and historical MM studies that showed the benefit of adding dexamethasone to bortezomib.(13-16) The objective of the current study was to determine”
BackgroundInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
The proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Waxman, A. J., Clasen, S., Hwang, W.-T., Garfall, A., Vogl, D. T., Carver, J., O’Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4519 · Cited by 286
Panobinostat for the Treatment of Multiple Myeloma
Laubach, J. P., Moreau, P., San-Miguel, J. F., & Richardson, P. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 255
Safety of proteasome inhibitors for treatment of multiple myeloma
Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1259310 · Cited by 71
“A phase II study of carfilzomib using the 20/56 mg/m(2) regimen reported a majority of grade 3/4 toxicities experienced by patients were hematologic; however, no patients discontinued carfilzomib due to hematologic adverse events [50].”
BackgroundMethodInfluential
Metadata
- Authors
- Lendvai, N., Hilden, P., Devlin, S., Landau, H., Hassoun, H., Lesokhin, A. M., Tsakos, I., Redling, K., Koehne, G., Chung, D. J., Schaffer, W. L., & Giralt, S. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-08-07
- Volume
- 124
- Issue
- 6
- Pages
- 899-906
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2050465851
- Cited by
- 82
- References
- 3
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2014-02-556308
- The paper
- Lendvai, N., Hilden, P., Devlin, S., Landau, H., Hassoun, H., Lesokhin, A. M., Tsakos, I., Redling, K., Koehne, G., Chung, D. J., Schaffer, W. L., & Giralt, S. A. (2014). A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. https://doi.org/10.1182/blood-2014-02-556308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.